Anthrax

Antibodies demonstrate efficacy against anthrax spore challenge

Published in Vaccine Weekly, October 22nd, 2003

Avanir Pharmaceuticals (AVN) said its Xenerex technology has generated multiple antibodies that demonstrate high potency against anthrax toxins in vitro and in vivo and against anthrax spores in vivo.

Mice protected by a single dose of one of Avanir's lead antibodies, AVP-8C1, against a lethal challenge of anthrax spores, were still completely protected on subsequent exposure to anthrax spores 4 weeks later. The immediate immunity conferred by the antibody appears to assist in the establishment of long-lasting immunity.

Phillip R. Morrow, PhD, co-inventor of Avanir's Xenerex technology and featured speaker at the Biophex conference, presented data in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry